![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
Under the award, Exvastat will collaborate with Vrije Universitat, Amsterdam Medical Center, KABS (Canada) and Simbec-Orion to produce a reformulated version of imatinib and test it in critically ill COVID-19 patients.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Innovative Medicines Initiative
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Funding May 15, 2020